These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20627789)

  • 21. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
    Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
    Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis.
    Danieli MG; Calcabrini L; Calabrese V; Marchetti A; Logullo F; Gabrielli A
    Autoimmun Rev; 2009 Dec; 9(2):124-7. PubMed ID: 19386287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous lupus erythematosus: update of therapeutic options part II.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e195-213. PubMed ID: 20800319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic strategies in idiopatic inflammatory myopathies].
    Chakour R; Leimgruber A; Bart PA; Spertini F
    Rev Med Suisse; 2009 Apr; 5(199):812-8. PubMed ID: 19441746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
    Basu B; Mahapatra TK; Mondal N
    Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Polymyositis/dermatomyositis--clinical picture and treatment].
    Anić B; Cerovec M
    Reumatizam; 2012; 59(2):44-50. PubMed ID: 23745455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease.
    Dalakas MC
    J Clin Immunol; 1995 Nov; 15(6 Suppl):70S-75S. PubMed ID: 8613495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab as a first-line agent for the treatment of dermatomyositis.
    Haroon M; Devlin J
    Rheumatol Int; 2012 Jun; 32(6):1783-4. PubMed ID: 20340018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current therapy for polymyositis and dermatomyositis].
    Chérin P
    Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment of the inflammatory myopathies.
    Dalakas MC
    Curr Opin Rheumatol; 1994 Nov; 6(6):595-601. PubMed ID: 7865379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
    Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
    Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
    An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myositis in clinical practice-relevance of new antibodies.
    Moghadam-Kia S; Aggarwal R; Oddis CV
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):887-901. PubMed ID: 31427061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dermatomyositis and polymyositis: clinical aspects and treatment].
    Hachulla E
    Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of idiopathic inflammatory myopathies.
    Amato AA; Griggs RC
    Curr Opin Neurol; 2003 Oct; 16(5):569-75. PubMed ID: 14501840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis and management of small vessel vasculitides].
    Pettersson T; Karjalainen A
    Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous dermatomyositis: an updated review of treatment options and internal associations.
    Femia AN; Vleugels RA; Callen JP
    Am J Clin Dermatol; 2013 Aug; 14(4):291-313. PubMed ID: 23754636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
    Efthimiou P; Schwartzman S; Kagen LJ
    Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review.
    Vermaak E; Tansley SL; McHugh NJ
    Clin Rheumatol; 2015 Dec; 34(12):2089-95. PubMed ID: 26299472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.